Shares of Sellas Life Sciences (SLS) jumped 3% on Monday as fresh filings showed that Opus Capital and Daiwa Securities boosted their stakes in the biotech company.SLS stock plunged 32% in July, logging its worst month since January 2024.Opus And Daiwa Boost Sellas StakesOpus Capital Group ended th…
Shares of Sellas Life Sciences Group (SLS) fell to a one-month low on Monday after the biotech firm lost its arbitration case against China partner 3D Medicines, but investors are already turning their attention back to the company’s closely watched Phase 3 leukemia trial.SLS stock fell 4% on Monda…
Shares of Sellas Life Sciences (SLS) climbed 1% premarket on Monday as investors weighed new big-money stake disclosures with the company nearing a potentially key Phase 3 catalyst for its acute myeloid leukemia (AML) drug.SLS stock fell 8% on Friday to $11.32, capping a 14% weekly decline and brin…
Shares of Sellas Life Sciences (SLS) rose 0.4% in overnight trading heading into Friday after a newly published acute myeloid leukemia (AML) study gave retail investors fresh ammunition in the debate over survival expectations for the drugmaker’s Regal trial.SLS stock rose 2% on Thursday to close a…
Shares of Sellas Life Sciences (SLS) are tracking their worst monthly performance since March as an investor trimmed more than 30% of its stake and Sellas enters a quiet period before key acute myeloid leukemia (AML) results.SLS stock rose 3% on Tuesday to close at $12.90, though shares remain down…
Shares of Sellas Life Sciences (SLS) rose 0.3% overnight late Monday after CEO Angelos Stergiou’s latest update sent retail investors dissecting every line for potential buyout clues, with references to a quiet period and database lock, reigniting takeover speculation ahead of his Friday appearance…
SELLAS Life Sciences (NASDAQ:SLS) says REGAL trial enrollment is slower than anticipated—potentially reflecting durable GPS benefit—and will announce the 80th event before topline results and enter a quiet period; the company holds $107.1M, raised $28.7M via warrants, updated executive terms, and f…
U.S. stock futures climbed higher in the overnight session late Sunday ahead of a key earnings week, even as the conflict between the U.S. and Iran escalated over the weekend.Nasdaq-100 futures climbed 0.45%, Dow futures were up 0.04%, and S&P 500 futures rose 0.14% at 9:11 PM EDT.Among ETFs tracki…
Shares of Sellas Life Sciences (SLS) snapped a two-day slide on Wednesday after the drugmaker’s updated SLS009 trial record put fresh attention on its second AML drug and its use of established cancer drugs from major pharma players.SLS stock rose 2% on Wednesday to end at $13.76, but shares headed…
Shares of Sellas Life Sciences (SLS) rose 1% overnight heading into Tuesday as retail traders picked the biotech firm as their top bullish bet among trending stocks, with attention fixed on the company’s looming Regal trial milestone.SLS stock fell 7% on Monday, ending the regular session at $13.94…
U.S. stock futures climbed higher in the overnight session late Sunday, extending the previous week’s rally as investors await the Federal Reserve’s June minutes due on Wednesday.Nasdaq 100 futures jumped 1.33%, S&P 500 futures climbed 0.53%, while Dow futures were up 0.15% at 8:11 PM EDT.Among ETF…
Shares of Sellas Life Sciences (SLS) came under pressure on Wednesday despite Endpoint Area, a clinical-trials prediction market, flashing 83% odds of a positive GPS result in acute myeloid leukemia (AML) and pointing to Nov. 30 as the expected catalyst.SLS stock slid 10% on Monday to end at $13.27…
Sellas Life Sciences’ record H1 rally has not scared retail traders into cashing out, with a new Stocktwits poll showing that most voters are still buying or holding as a key acute myeloid leukemia (AML) trial nears its final readout.SLS stock surged 292% in the first half, topping its H1 performan…
Shares of Sellas Life Sciences Group Inc. (SLS), BlackBerry Ltd. (BB), and Ouster Inc. (OUST) jumped to 52-week highs on Monday amid a series of positive catalysts and optimistic growth outlooks.SLS stock soared more than 24% at close on Monday as investors looked ahead to the company’s Phase 3 REG…
Shares of Sellas Life Sciences (SLS) hit their highest level in over five years on Monday as retail traders showed strong confidence in the stock’s 12-month upside ahead of the company’s closely watched acute myeloid leukemia (AML) trial readout.SLS stock jumped 25% on Monday to close at $15.45, ex…
